Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | REV1 | Q9UBZ9 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2213404 | 0.86 | MAPT (0.38) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2535091 | 0.81 | SMN1; SMN2 (0.37) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12436051 | 0.81 | KDM4E (0.43) | KDM4EMAPTEPHX2EPHX1SMN1; SMN2 | |
| SCHEMBL428708 | 0.80 | — | — | |
| SCHEMBL31623264 | 0.80 | HSD11B1 (0.33) | — | |
| SCHEMBL12050687 | 0.80 | SMN1; SMN2 (0.33) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL895391 | 0.79 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL586633 | 0.79 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL969838 | 0.79 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL407899 | 0.79 | HPGD (0.56) | KDM4EMAPTEPHX1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440078-B1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD (IN) | 2022-09-28 | — | — | EP | disclosed |
| CN-109415359-B | Heterocyclic GPR119 agonist compounds | 人类制药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| EP-3057951-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-20 | — | — | EP | disclosed |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2019-05-02 | — | — | US | disclosed |
| EP-2173745-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-2013204-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1986645-A1 | GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008118718-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008091770-A1 | 2-AMINOPYRIDINE DERIVATIVES AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2007117381-A9 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007117381-A2 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007089512-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | KDM4E 2457/4885MAPT 4134/4885EPHX2 921/4885 |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | KDM4E 2939/4885MAPT 4375/4885EPHX2 4710/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | KDM4E 1622/4885MAPT 3414/4885EPHX2 4703/4885 |
| US-10752622-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | KDM4E 3042/4885MAPT 4084/4885EPHX2 1109/4885 |
| US-10954229-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | KDM4E 3042/4885MAPT 4084/4885EPHX2 1109/4885 |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | KDM4E 2457/4885MAPT 4134/4885EPHX2 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.